A Mini-Review of Human Studies on Cholesterol-Lowering Properties of Probiotics
Abstract
1. Introduction
2. Impact of Probiotic Supplementation on the Lipid Profile of the Human Subjects
2.1. Hypercholesterolemic Subjects
2.2. Healthy Subjects
2.3. Diabetes Patients
2.4. Other Subjects
3. Meta-Analysis Studies
4. Effect of Probiotics Supplementation on Lipid Profile: Non-Significant Outcomes
5. Opinion on the Hypocholesterolemic Effect of Reviewed Probiotics
6. Concluding Remarks
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Benjamin, E.J.; Virani, S.S.; Callaway, C.W.; Chang, A.R.; Cheng, S.; Chiuve, S.E.; Cushman, M.; Delling, F.N.; Deo, R.; de Ferranti, S.D.; et al. Heart disease and stroke statistics—2018 update: A report from the American heart association. Circulation 2018, 137, e67–e492. [Google Scholar] [CrossRef] [PubMed]
- Heidenreich, P.A.; Trogdon, J.G.; Khavjou, O.A.; Butler, J.; Dracup, K.; Ezekowitz, M.D.; Finkelstein, E.A.; Hong, Y.; Johnston, S.C.; Khera, A.; et al. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American heart association. Circulation 2011, 123, 933–944. [Google Scholar] [CrossRef] [PubMed]
- Sun, J.; Buys, N. Effects of probiotics consumption on lowering lipids and CVD risk factors: A systematic review and meta-analysis of randomized controlled trials. Ann. Med. 2015, 47, 430–440. [Google Scholar] [CrossRef] [PubMed]
- Scavuzzi, B.M.; Miglioranza, L.H.D.S.; Henrique, F.C.; Paroschi, T.P.; Lozovoy, M.A.B.; Simão, A.N.C.; Dichi, I. The role of probiotics on each component of the metabolic syndrome and other cardiovascular risks. Expert Opin. Ther. Targets 2015, 19, 1127–1138. [Google Scholar] [CrossRef] [PubMed]
- Tang, W.H.; Hazen, S.L. The gut microbiome and its role in cardiovascular diseases. Circulation. 2017, 135, 1008–1010. [Google Scholar] [CrossRef] [PubMed]
- Yoshida, N.; Yamashita, T.; Hirata, K.I. Gut microbiome and cardiovascular diseases. Diseases 2018, 6, 56. [Google Scholar] [CrossRef] [PubMed]
- Hill, C.; Guarner, F.; Reid, G.; Gibson, G.R.; Merenstein, D.J.; Pot, B.; Morelli, L.; Canani, R.B.; Flint, H.J.; Salminen, S.; et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014, 11, 506–514. [Google Scholar] [CrossRef]
- Food and Agriculture Organization of the United Nations; World Health Organization. Probiotics in food: Health and nutritional properties and guidelines for evaluation. FAO Food Nutr. Pap. 2006, 85, 1–50. [Google Scholar]
- Degnan, F.H. The US food and drug administration and probiotics: Regulatory categorization. Clin. Infect. Dis. 2008, 46, S133–S136. [Google Scholar] [CrossRef]
- Venugopalan, V.; Shriner, K.A.; Wong-Beringer, A. Regulatory oversight and safety of probiotic use. Emerg. Infect. Dis. 2010, 16, 1661–1665. [Google Scholar] [CrossRef]
- Sivamaruthi, B.S. A comprehensive review on clinical outcome of probiotic and synbiotic therapy for inflammatory bowel diseases. Asian Pac. J. Trop. Biomed. 2018, 8, 179–186. [Google Scholar] [CrossRef]
- Sivamaruthi, B.S.; Kesika, P.; Prasanth, M.I.; Chaiyasut, C. A mini review on antidiabetic properties of fermented foods. Nutrients 2018, 10, 1973. [Google Scholar] [CrossRef] [PubMed]
- Sivamaruthi, B.S.; Kesika, P.; Suganthy, N.; Chaiyasut, C. A review on role of microbiome in obesity and antiobesity properties of probiotic supplements. BioMed Res. Int. 2019, 2019, 3291367. [Google Scholar] [CrossRef] [PubMed]
- Blaabjerg, S.; Artzi, D.M.; Aabenhus, R. Probiotics for the prevention of antibiotic-associated diarrhea in outpatients—A systematic review and meta-analysis. Antibiotics 2017, 6, 21. [Google Scholar] [CrossRef] [PubMed]
- Sivamaruthi, B.S.; Kesika, P.; Chaiyasut, C. Influence of probiotic supplementation on climacteric symptoms in menopausal women—A mini review. Int. J. Appl. Pharm. 2018, 10, 43–46. [Google Scholar] [CrossRef]
- Sivamaruthi, B.S.; Kesika, P.; Chaiyasut, C. Probiotic based therapy for atopic dermatitis: Outcomes of clinical studies. Asian Pac. J. Trop. Biomed. 2018, 8, 328–332. [Google Scholar] [CrossRef]
- Sivamaruthi, B.S.; Prasanth, M.I.; Kesika, P.; Chaiyasut, C. Probiotics in human mental health and diseases—A mini review. Trop. J. Pharm. Res. 2019, 18, 889–895. [Google Scholar]
- Sivamaruthi, B.S.; Kesika, P.; Chaiyasut, C. A review on anti-aging properties of probiotics. Int. J. Appl. Pharm. 2018, 10, 23–27. [Google Scholar] [CrossRef]
- Mikelsaar, M.; Sepp, E.; Štšepetova, J.; Songisepp, E.; Mändar, R. Biodiversity of intestinal lactic acid bacteria in the healthy population. In Advances in Microbiology, Infectious Diseases and Public Health; Springer: Cham, Switzerland, 2016; Volume 932, pp. 1–64. [Google Scholar]
- Upadrasta, A.; Madempudi, R.S. Probiotics and blood pressure: Current insights. Integr. Blood Press. Control 2016, 9, 33–42. [Google Scholar]
- Ooi, L.G.; Liong, M.T. Cholesterol-lowering effects of probiotics and prebiotics: A review of in vivo and in vitro findings. Int. J. Mol. Sci. 2010, 11, 2499–2522. [Google Scholar] [CrossRef]
- Le, B.; Yang, S.H. Identification of a novel potential probiotic Lactobacillus plantarum FB003 isolated from salted-fermented shrimp and its effect on cholesterol absorption by regulation of NPC1L1 and PPARα. Probiotics Antimicrob. Proteins 2018, 11, 785–793. [Google Scholar] [CrossRef] [PubMed]
- Nami, Y.; Bakhshayesh, R.V.; Manafi, M.; Hejazi, M.A. Hypocholesterolaemic activity of a novel autochthonous potential probiotic Lactobacillus plantarum YS5 isolated from yogurt. LWT 2019, 111, 876–882. [Google Scholar] [CrossRef]
- Cavallini, D.C.; Manzoni, M.S.; Bedani, R.; Roselino, M.N.; Celiberto, L.S.; Vendramini, R.C.; de Valdez, G.; Abdalla, D.S.; Pinto, R.A.; Rosetto, D.; et al. Probiotic soy product supplemented with isoflavones improves the lipid profile of moderately hypercholesterolemic men: A randomized controlled trial. Nutrients 2016, 8, 52. [Google Scholar] [CrossRef] [PubMed]
- Fuentes, M.C.; Lajo, T.; Carrion, J.M.; Cune, J. A randomized clinical trial evaluating a proprietary mixture of Lactobacillus plantarum strains for lowering cholesterol. Med. J. Nutr. Metab. 2016, 9, 125–135. [Google Scholar] [CrossRef]
- Guardamagna, O.; Amaretti, A.; Puddu, P.E.; Raimondi, S.; Abello, F.; Cagliero, P.; Rossi, M. Bifidobacteria supplementation: Effects on plasma lipid profiles in dyslipidemic children. Nutrition 2014, 30, 831–836. [Google Scholar] [CrossRef]
- Hlivak, P.; Odraska, J.; Ferencik, M.; Ebringer, L.; Jahnova, E.; Mikes, Z. One-year application of probiotic strain Enterococcus faecium M-74 decreases serum cholesterol levels. Bratisl Lek. Listy 2005, 106, 67–72. [Google Scholar]
- Rerksuppaphol, S.; Rerksuppaphol, L. A randomized double-blind controlled trial of Lactobacillus acidophilus plus Bifidobacterium bifidum versus placebo in patients with hypercholesterolemia. J. Clin. Diagn. Res. 2015, 9, KC01–KC04. [Google Scholar] [CrossRef]
- Ryan, J.J.; Hanes, D.A.; Schafer, M.B.; Mikolai, J.; Zwickey, H. Effect of the probiotic Saccharomyces boulardii on cholesterol and lipoprotein particles in hypercholesterolemic adults: A single-arm, open-label pilot study. J. Altern. Complement. Med. 2015, 21, 288–293. [Google Scholar] [CrossRef]
- Kekkonen, R.A.; Sysi-Aho, M.; Seppanen-Laakso, T.; Julkunen, I.; Vapaatalo, H.; Oresic, M.; Korpela, R. Effect of probiotic Lactobacillus rhamnosus GG intervention on global serum lipidomic profiles in healthy adults. World J. Gastroenterol. 2008, 14, 3188–3194. [Google Scholar] [CrossRef]
- Moradi, S.M.; Javidan, A.; Isfahani, H.N. Effects of probiotic ultra-filtered feta cheese and raw chicory root extract on lipid profile in healthy adult volunteers: A triple-blinded randomized controlled trial. Mediterr. J. Nutr. Metab. 2013, 6, 199–206. [Google Scholar] [CrossRef]
- Ejtahed, H.S.; Mohtadi-Nia, J.; Homayouni-Rad, A.; Niafar, M.; Asghari-Jafarabadi, M.; Mofid, V.; Akbarian-Moghari, A. Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J. Dairy Sci. 2011, 94, 3288–3294. [Google Scholar] [CrossRef] [PubMed]
- Karamali, M.; Dadkhah, F.; Sadrkhanlou, M.; Jamilian, M.; Ahmadi, S.; Tajabadi-Ebrahimi, M.; Jafari, P.; Asemi, Z. Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: A randomized, double-blind, placebo-controlled trial. Diabetes Metab. 2016, 42, 234–241. [Google Scholar] [CrossRef] [PubMed]
- Tonucci, L.B.; dos Santos, K.M.O.; de Oliveira, L.L.; Ribeiro, S.M.R.; Martino, H.S.D. Clinical application of probiotics in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. Clin. Nutr. 2017, 36, 85–92. [Google Scholar] [CrossRef] [PubMed]
- Abbasi, B.; Mirlohi, M.; Daniali, M.; Ghiasvand, R. Effects of probiotic soymilk on lipid panel in type 2 diabetic patients with nephropathy: A double-blind randomized clinical trial. Prog. Nutr. 2018, 20, 70–78. [Google Scholar]
- Kassaian, N.; Feizi, A.; Aminorroaya, A.; Amini, M. Probiotic and synbiotic supplementation could improve metabolic syndrome in prediabetic adults: A randomized controlled trial. Diabetes Metab. Syndr. 2018. [Google Scholar] [CrossRef]
- Mafi, A.; Namazi, G.; Soleimani, A.; Bahmani, F.; Aghadavod, E.; Asemi, Z. Metabolic and genetic response to probiotics supplementation in patients with diabetic nephropathy: A randomized, double-blind, placebo-controlled trial. Food Funct. 2018, 9, 4763–4770. [Google Scholar] [CrossRef]
- Sabico, S.; Al-Mashharawi, A.; Al-Daghri, N.M.; Wani, K.; Amer, O.E.; Hussain, D.S.; Ahmed Ansari, M.G.; Masoud, M.S.; Alokail, M.S.; McTernan, P.G. Effects of a 6-month multi-strain probiotics supplementation in endotoxemic, inflammatory and cardiometabolic status of T2DM patients: A randomized, double-blind, placebo-controlled trial. Clin. Nutr. 2019, 38, 1561–1569. [Google Scholar] [CrossRef]
- Szulińska, M.; Łoniewski, I.; van Hemert, S.; Sobieska, M.; Bogdański, P. Dose-dependent effects of multispecies probiotic supplementation on the lipopolysaccharide (LPS) level and cardiometabolic profile in obese postmenopausal women: A 12-week randomized clinical trial. Nutrients 2018, 10, 773. [Google Scholar] [CrossRef]
- Minami, J.; Iwabuchi, N.; Tanaka, M.; Yamauchi, K.; Xiao, J.Z.; Abe, F.; Sakane, N. Effects of Bifidobacterium breve B-3 on body fat reductions in pre-obese adults: A randomized, double-blind, placebo-controlled trial. Biosci. Microbiota Food Health 2018, 37, 67–75. [Google Scholar] [CrossRef]
- Kim, J.; Yun, J.M.; Kim, M.K.; Kwon, O.; Cho, B. Lactobacillus gasseri BNR17 supplementation reduces the visceral fat accumulation and waist circumference in obese adults: A randomized, double-blind, placebo-controlled trial. J. Med. Food 2018, 21, 454–461. [Google Scholar] [CrossRef]
- Guo, Z.; Liu, X.M.; Zhang, Q.X.; Shen, Z.; Tian, F.W.; Zhang, H.; Sun, Z.H.; Zhang, H.P.; Chen, W. Influence of consumption of probiotics on the plasma lipid profile: A meta-analysis of randomised controlled trials. Nutr. Metab. Cardiovasc. Dis. 2011, 21, 844–850. [Google Scholar] [CrossRef] [PubMed]
- Cho, Y.A.; Kim, J. Effect of probiotics on blood lipid concentrations: A meta-analysis of randomized controlled trials. Medicine 2015, 94, e1714. [Google Scholar] [CrossRef] [PubMed]
- Shimizu, M.; Hashiguchi, M.; Shiga, T.; Tamura, H.-O.; Mochizuki, M. Meta-analysis: Effects of probiotic supplementation on lipid profiles in normal to mildly hypercholesterolemic individuals. PLoS ONE 2015, 10, e0139795. [Google Scholar] [CrossRef] [PubMed]
- Sharma, S.; Kurpad, A.V.; Puri, S. Potential of probiotics in hypercholesterolemia: A meta‑analysis. Indian J. Public Health 2016, 60, 280–286. [Google Scholar] [PubMed]
- Wu, Y.; Zhang, Q.; Ren, Y.; Ruan, Z. Effect of probiotic Lactobacillus on lipid profile: A systematic review and meta-analysis of randomized, controlled trials. PLoS ONE 2017, 12, e0178868. [Google Scholar] [CrossRef]
- Wang, L.; Guo, M.-J.; Gao, Q.; Yang, J.-F.; Yang, L.; Pang, X.-L.; Jiang, X.-J. The effects of probiotics on total cholesterol: A meta-analysis of randomized controlled trials. Medicine 2018, 97, e9679. [Google Scholar] [CrossRef]
- Dong, Y.; Xu, M.; Chen, L.; Bhochhibhoya, A. Probiotic foods and supplements interventions for metabolic syndromes: A systematic review and meta-analysis of recent clinical trials. Ann. Nutr. Metab. 2019, 74, 224–241. [Google Scholar] [CrossRef]
- Gao, X.; Zhu, Y.; Wen, Y.; Liu, G.; Wan, C. Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials. Hepatol. Res. 2016, 46, 1226–1233. [Google Scholar] [CrossRef]
- Hendijani, F.; Akbari, V. Probiotic supplementation for management of cardiovascular risk factors in adults with type II diabetes: A systematic review and meta-analysis. Clin. Nutr. 2018, 37, 532–541. [Google Scholar] [CrossRef]
- He, J.; Zhang, F.; Han, Y. Effect of probiotics on lipid profiles and blood pressure in patients with type 2 diabetes: A meta-analysis of RCTs. Medicine 2017, 96, e9166. [Google Scholar] [CrossRef]
- Mahboobi, S.; Rahimi, F.; Jafarnejad, S. Effects of prebiotic and synbiotic supplementation on glycaemia and lipid profile in type 2 diabetes: A meta-analysis of randomized controlled trials. Adv. Pharm. Bull. 2018, 8, 565–574. [Google Scholar] [CrossRef] [PubMed]
- Lewis, S.J.; Burmeister, S. A double-blind placebo-controlled study of the effects of Lactobacillus acidophilus on plasma lipids. Eur. J. Clin. Nutr. 2005, 59, 776–780. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.; Ba, Z.; Roberts, R.F.; Rogers, C.J.; Fleming, J.A.; Meng, H.; Furumoto, E.J.; Kris-Etherton, P.M. Effects of Bifidobacterium animalis subsp. lactis BB-12® on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: A randomized controlled trial. Nutr. J. 2017, 16, 39. [Google Scholar] [CrossRef] [PubMed]
- Ivey, K.L.; Hodgson, J.M.; Kerr, D.A.; Thompson, P.L.; Stojceski, B.; Prince, R.L. The effect of yoghurt and its probiotics on blood pressure and serum lipid profile; a randomised controlled trial. Nutr. Metab. Cardiovasc. Dis. 2015, 25, 46–51. [Google Scholar] [CrossRef] [PubMed]
- Greany, K.A.; Bonorden, M.J.; Hamilton-Reeves, J.M.; McMullen, M.H.; Wangen, K.E.; Phipps, W.R.; Feirtag, J.; Thomas, W.; Kurzer, M.S. Probiotic capsules do not lower plasma lipids in young women and men. Eur. J. Clin. Nutr. 2008, 62, 232–237. [Google Scholar] [CrossRef] [PubMed]
- Culpepper, T.; Rowe, C.C.; Rusch, C.T.; Burns, A.M.; Federico, A.P.; Girard, S.A.; Tompkins, T.A.; Nieves, C., Jr.; Dennis-Wall, J.C.; Christman, M.C.; et al. Three probiotic strains exert different effects on plasma bile acid profiles in healthy obese adults: Randomised, double-blind placebo-controlled crossover study. Benef. Microbes 2019, 10, 497–509. [Google Scholar] [CrossRef]
- Asemi, Z.; Zare, Z.; Shakeri, H.; Sabihi, S.S.; Esmaillzadeh, A. Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Ann. Nutr. Metab. 2013, 63, 1–9. [Google Scholar] [CrossRef]
- Mahboobi, S.; Iraj, B.; Maghsoudi, Z.; Feizi, A.; Ghiasvand, R.; Askari, G.; Maayeshi, N. The effects of probiotic supplementation on markers of blood lipids, and blood pressure in patients with prediabetes: A randomized clinical trial. Int. J. Prev. Med. 2014, 5, 1239–1246. [Google Scholar]
- Razmpoosh, E.; Javadi, A.; Ejtahed, H.S.; Mirmiran, P.; Javadi, M.; Yousefinejad, A. The effect of probiotic supplementation on glycemic control and lipid profile in patients with type 2 diabetes: A randomized placebo controlled trial. Diabetes Metab. Syndr. Clin. Res. Rev. 2019, 13, 175–182. [Google Scholar] [CrossRef]
- Ebrahimi, Z.S.; Nasli-Esfahani, E.; Nadjarzade, A.; Mozaffari-Khosravi, H. Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: A randomized, double-blind, clinical trial. J. Diabetes Metab. Disord. 2017, 16, 23. [Google Scholar] [CrossRef]
- Mazloom, Z.; Yousefinejad, A.; Dabbaghmanesh, M.H. Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: A clinical trial. Iran. J. Med. Sci. 2013, 38, 38–43. [Google Scholar] [PubMed]
- Sabico, S.; Al-Mashharawi, A.; Al-Daghri, N.M.; Yakout, S.; Alnaami, A.M.; Alokail, M.S.; McTernan, P.G. Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naïve T2DM patients: A randomized clinical trial. J. Transl. Med. 2017, 15, 249. [Google Scholar] [CrossRef] [PubMed]
- Ishimwe, N.; Daliri, E.B.; Lee, B.H.; Fang, F.; Du, G. The perspective on cholesterol-lowering mechanisms of probiotics. Mol. Nutr. Food Res. 2015, 59, 94–105. [Google Scholar] [CrossRef] [PubMed]
Study | Subjects | Diet | Intervention | Dosage | Duration | Findings | Ref. |
---|---|---|---|---|---|---|---|
RPCDB | Healthy male individuals with moderate hypercholesterolemia; n = 49; Age = 37 to 57 years | No changes in the usual diet | Fermented soy product containing Enterococcus faecium CRL 183, and Lactobacillus helveticus 416 and isoflavone | 200 ml per day (1010 CFU/ day) | 42 days |
| [24] |
RPCDB | Adults with hypercholesterolemia; n = 60 (34 male, 26 female); Age = 18 to 65 years | No specific diet | Lactobacillus plantarum (3 strains) | 100 mg of the probiotic mixture (1010 CFU during production) per capsule; 1 capsule/ day | 12 weeks |
| [25] |
RPCDB | Dyslipidemic children; Age = 6 to 18 years | STEP 1 diet (normal caloric diet) | Bifidobacterium animalis subsp. lactis MB 2409, B. bifidum MB 109B, and B. longum BL04 | 3 strains (each 109 CFU) within one capsule/ day | 3 months |
| [26] |
RPCDB | Elderly people; n = 38 (7 male, 31 female); Age = 70 to 80 years | No specific diet | E. faecium M-74 and selenium | 2 × 109 CFU of probiotic and 50 µg selenium per capsule/ day | 1 year |
| [27] |
RPCDB | Hypercholesterolemic patients; n = 64 (male); Age = 40 to 60 years | Minimum calorie diet with minimal intake of lipid | L. acidophilus and B. bifidum | 3 capsule/day; Each strain 109 CFU/capsule | 6 weeks |
| [28] |
Single-Arm, Open-Label Study | Healthy adults with hypercholesterolemia; n = 11 (10 male, 1 female); Age = 21 to 69 years | No changes in the usual diet | Saccharomyces cerevisiae var. boulardii CNCM I-1079 | 4 capsules twice a day; 1.4 × 1010 CFU/capsule | 8 weeks |
| [29] |
RPCDB | Healthy people; n = 26 (12 male, 14 female); Age = 23 to 55 years | No specific diet | L. rhamnosus GG | 250 ml probiotic drink/day (6.2 × 107 CFU/ ml) | 3 weeks |
| [30] |
RPCDB | Healthy people; n = 180 (90 male, 90 female); Age = 18 to 65 years | Consumption of low-fat milk for a week before the trial begins | L. acidophilus LA5 and B. lactis BB12 + chicory root extract | 30 g probiotic cheese (each strain 5 × 106 CFU) and 30 g of chicory root extract | 7 weeks |
| [31] |
RPCDB | Individuals with T2D; n = 60 (23 male, 37 female); Age = 30 to 60 years | No changes in the usual diet | Probiotic yogurt with L. acidophilus, La5 and B. lactis Bb12 | 300 g of yogurt per day | 6 weeks |
| [32] |
RPCDB | Gestational diabetic patients; n = 60; Age = 18 to 40 years | No changes in the usual diet | L. acidophilus, L. casei and B. bifidum | One capsule (Each strain 2 × 109 CFU/g) per day | 6 weeks |
| [33] |
RPCDB | Individuals with T2D; n = 45 (26 male, 19 female); Age = 35 to 60 years | No changes in the usual diet | Fermented milk with L. acidophilus La-5 and B. animalis subsp. lactis BB-12 | 120 g of fermented milk per day; (Each strain 109 CFU/day) | 6 weeks |
| [34] |
RPCDB | T2D patients; n = 40 (19 male, 21 female); Age = 40 to 70 years | Diet (consists of 0.8 g/kg protein, 2 g potassium, 1.5 g phosphorus, and 2 g sodium) | Soy milk containing L. plantarum A7 | 200 ml of probiotic soy milk/ day; 2 × 107 CFU/ml | 8 weeks |
| [35] |
RPCDB | Pre-diabetic subjects; n = 120 (50 male, 70 female); Age = 35 to 70 years | No changes in the usual diet | L. acidophilus, B. bifidum, B. lactis, and B. longum | 6 g per day (Each strain 1.5 ×109 CFU/day) | 24 weeks |
| [36] |
RPCDB | Diabetic nephropathy patients; n = 60; Age = 45 to 85 years | No changes in the usual diet | L. acidophilus ZT-L1, L. reuteri ZT-Lre, L. fermentum ZT-L3 and B. bifidum ZT-B1 | 8 × 109 CFU/day (Each strain 2 × 109 CFU/ day) | 12 weeks |
| [37] |
RPCDB | T2D patients; n = 61 (26 male, 35 female); Age = 35 to 70 years | No changes in the usual diet | B. bifidum W23, B. lactis W51, and W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lactococcus lactis W19 and W58 | 2 g of the probiotic mixture (2.5 × 109 CFU/g) per day | 6 months |
| [38] |
RPCDB | Obese postmenopausal women; n = 71; Age = 45 to 70 years | No changes in the usual diet | B. bifidum W23, B. lactis W51, and W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lactococcus lactis W19 and W58 | 2 g of the probiotic mixture (high dose: 1 × 1010 CFU; low dose: 2.5 × 109 CFU) per day | 12 weeks |
| [39] |
RPCDB | Healthy pre-obese adults; n = 80 (74 male, 6 female); Age = 35 to 56 years | No changes in usual diet | B. breve B-3 | 2 capsule per day; 10 × 109 CFU per capsule | 12 weeks |
| [40] |
RPCDB | Obese adults; n = 90 (27 male, 63 female); Age = 20 to 75 years | As per dietitian instruction, subjects reduced 200 kcal from their usual diet every day | Lactobacillus gasseri BNR17 | 2 capsules (high dose: 1 × 1010 CFU; low dose: 1 × 109 CFU) per day; 400 mg per capsule | 12 weeks |
| [41] |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sivamaruthi, B.S.; Kesika, P.; Chaiyasut, C. A Mini-Review of Human Studies on Cholesterol-Lowering Properties of Probiotics. Sci. Pharm. 2019, 87, 26. https://doi.org/10.3390/scipharm87040026
Sivamaruthi BS, Kesika P, Chaiyasut C. A Mini-Review of Human Studies on Cholesterol-Lowering Properties of Probiotics. Scientia Pharmaceutica. 2019; 87(4):26. https://doi.org/10.3390/scipharm87040026
Chicago/Turabian StyleSivamaruthi, Bhagavathi Sundaram, Periyanaina Kesika, and Chaiyavat Chaiyasut. 2019. "A Mini-Review of Human Studies on Cholesterol-Lowering Properties of Probiotics" Scientia Pharmaceutica 87, no. 4: 26. https://doi.org/10.3390/scipharm87040026
APA StyleSivamaruthi, B. S., Kesika, P., & Chaiyasut, C. (2019). A Mini-Review of Human Studies on Cholesterol-Lowering Properties of Probiotics. Scientia Pharmaceutica, 87(4), 26. https://doi.org/10.3390/scipharm87040026